Dr
John Montana
John is Chief Scientific Officer of Argenta Discovery.
During his career, John has worked in large, multinational pharmaceutical organisations and small, entrepreneurial biotechnology companies. He joined Argenta from the drug discovery company Paradigm Therapeutics, where he became Chief Scientific Officer in January 2005 when the company acquired Amedis. Prior to that he spent three years as Chief Executive Officer of Amedis, spearheading its growth and development into a successful medicinal chemistry-based drug discovery organisation.
Previously, John worked for Chiroscience as Head of Chemistry, where he was instrumental in establishing a research strategy that delivered six development compounds in the same number of years. He also played a major role in brokering and managing a number of collaborations with major pharmaceutical and biotechnology companies. He built all aspects of the company's chemistry operations (medicinal, computational, combinatorial) from inception and established state-of-the-art laboratories. Following the merger of Chiroscience and Celltech, John became Director of NCE Research with overall responsibility for the company's NCE portfolio, comprising 15-20 projects at various stages of research.
A medicinal chemist by training, John began his career at Glaxo, where he carried out research across a range of therapeutic areas, including Respiratory diseases, Central Nervous System disorders, Cardiovascular illnesses and Gastro-Intestinal diseases.
Argenta Discovery Limited is a company incorporated and registered in England with registered number 3671653 whose registered office and principal place of business is at 8/9 Spire Green Centre, Flex Meadow, Harlow, CM19 5TR, United Kingdom and whose VAT registration number is GB 848 2268 02.